A citation-based method for searching scientific literature

Takaaki Oba, Tatsunori Chino, Ai Soma, Tadafumi Shimizu, Mayu Ono, Tokiko Ito, Toshiharu Kanai, Kazuma Maeno, Ken-Ichi Ito. Endocr J 2020
Times Cited: 6







List of co-cited articles
8 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
33

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
496
33

Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism.
Alessio Basolo, Antonio Matrone, Rossella Elisei, Ferruccio Santini. Semin Cancer Biol 2022
8
33

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
33

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
673
33

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, Bruce Robinson, Furio Pacini, Douglas W Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G Martins,[...]. Clin Cancer Res 2016
137
33

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
974
33

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
858
33

Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry.
Kiho You, Sungmin Park, Jai Min Ryu, Isaac Kim, Se Kyung Lee, Jonghan Yu, Seok Won Kim, Seok Jin Nam, Jeong Eon Lee. J Breast Cancer 2017
22
16

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
16

Ki67 in breast cancer: prognostic and predictive potential.
Rinat Yerushalmi, Ryan Woods, Peter M Ravdin, Malcolm M Hayes, Karen A Gelmon. Lancet Oncol 2010
729
16

Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer.
A Gil-Rendo, F Martínez-Regueira, G Zornoza, M J García-Velloso, C Beorlegui, N Rodriguez-Spiteri. Br J Surg 2009
119
16

A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
Fangfang Zhong, Rui Bi, Baohua Yu, Fei Yang, Wentao Yang, Ruohong Shui. PLoS One 2016
42
16

Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?
Concetta De Cicco, Laura Gilardi, Edoardo Botteri, Silvia L V Fracassi, Giuseppina A Di Dia, Francesca Botta, Gennaro Prisco, Dario Lombardo, Nicole Rotmensz, Umberto Veronesi,[...]. Breast 2013
23
16

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
16

Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
Anna Sutela, Ritva Vanninen, Mazen Sudah, Marja Berg, Vesa Kiviniemi, Jaana Rummukainen, Vesa Kataja, Vesa Kärjä. Acta Oncol 2008
34
16

A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells.
Takaaki Oba, Toshifumi Hoki, Takayoshi Yamauchi, Tibor Keler, Henry C Marsh, Xuefang Cao, Fumito Ito. J Immunol 2020
11
16

Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Shigeto Ueda, Hitoshi Tsuda, Toshiaki Saeki, Jiro Omata, Akihiko Osaki, Takashi Shigekawa, Jiro Ishida, Katsumi Tamura, Yoshiyuki Abe, Tomoyuki Moriya,[...]. Breast Cancer 2011
28
16

Reliability of core needle biopsy for determining ER and HER2 status in breast cancer.
T J A Dekker, V T H B M Smit, G K J Hooijer, M J Van de Vijver, W E Mesker, R A E M Tollenaar, J W R Nortier, J R Kroep. Ann Oncol 2013
48
16


Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast.
Maiko Ito, Tadahiko Shien, Mitsumasa Kaji, Taeko Mizoo, Takayuki Iwamoto, Tomohiro Nogami, Takayuki Motoki, Naruto Taira, Hiroyoshi Doihara, Shinichiro Miyoshi. Acta Med Okayama 2015
6
16


Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
Elena Vissio, Jasna Metovic, Simona Osella-Abate, Luca Bertero, Giuseppe Migliaretti, Fulvio Borella, Chiara Benedetto, Anna Sapino, Paola Cassoni, Isabella Castellano. Br J Cancer 2020
8
16

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.
Andreas Buck, Holger Schirrmeister, Thorsten Kühn, Changxian Shen, Thomas Kalker, Jörg Kotzerke, Anja Dankerl, Gerhard Glatting, Sven Reske, Torsten Mattfeldt. Eur J Nucl Med Mol Imaging 2002
216
16

Proliferation marker Ki-67 in early breast cancer.
Ander Urruticoechea, Ian E Smith, Mitch Dowsett. J Clin Oncol 2005
564
16

Comparison between Ki67 labeling index determined using image analysis software with virtual slide system and that determined visually in breast cancer.
Ichiro Maeda, Kayoko Abe, Hirotaka Koizumi, Chika Nakajima, Shinya Tajima, Hiromi Aoki, Junichi Tsuchiya, Seiko Tsuchiya, Kyoko Tsuchiya, Arata Shimo,[...]. Breast Cancer 2016
16
16

Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
Xiaosong Chen, Siji Zhu, Xiaochun Fei, David H Garfield, Jiayi Wu, Ou Huang, Yafen Li, Li Zhu, Jianrong He, Weiguo Chen,[...]. BMC Cancer 2015
24
16


CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment.
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Hidehito Saito, Kristopher Attwood, Michael S Sabel, Alfred E Chang, Kunle Odunsi, Fumito Ito. JCI Insight 2020
18
16

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
E de Azambuja, F Cardoso, G de Castro, M Colozza, M S Mano, V Durbecq, C Sotiriou, D Larsimont, M J Piccart-Gebhart, M Paesmans. Br J Cancer 2007
604
16

The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast.
Zsolt Hodi, Jayeta Chakrabarti, Andrew H S Lee, John E Ronan, Christopher W Elston, Kwok Leung Cheung, John F R Robertson, Ian O Ellis. J Clin Pathol 2007
54
16

The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer.
So Yeon Park, Ku Sang Kim, Taek-Gu Lee, Sung-Shin Park, Sun Mi Kim, Wonshik Han, Dong-Young Noh, Sung-Won Kim. Am J Surg 2009
48
16

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, A Goldhirsch, R D Gelber, M Gnant, M Piccart-Gebhart, B Thürlimann, H-J Senn. Ann Oncol 2015
16

Strategies for developing Ki67 as a useful biomarker in breast cancer.
Carsten Denkert, Jan Budczies, Gunter von Minckwitz, Stephan Wienert, Sibylle Loibl, Frederick Klauschen. Breast 2015
106
16

Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.
Veronique Lorgis, Marie Paule Algros, Cristian Villanueva, Loic Chaigneau, Antoine Thierry-Vuillemin, Thierry Nguyen, Martin Demarchi, Fernando Bazan, Jean Loup Sautiere, Yolande Maisonnette-Lescot,[...]. Breast 2011
48
16

The relationship between FDG uptake in PET scans and biological behavior in breast cancer.
Wataru Shimoda, Mitsuhiro Hayashi, Koji Murakami, Tetsunari Oyama, Masakatsu Sunagawa. Breast Cancer 2007
72
16

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
C Denkert, S Loibl, B M Müller, H Eidtmann, W D Schmitt, W Eiermann, B Gerber, H Tesch, J Hilfrich, J Huober,[...]. Ann Oncol 2013
148
16

Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner,[...]. N Engl J Med 2008
16

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
P Ghatalia, Y Je, M D Kaymakcalan, G Sonpavde, T K Choueiri. Br J Cancer 2015
79
16

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis.
Kirsi M Manz, Klaus Fenchel, Andreas Eilers, Jonathan Morgan, Kirsten Wittling, Wolfram C M Dempke. Adv Ther 2020
6
16

Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Pooja Ghatalia, Charity J Morgan, Youjin Je, Paul L Nguyen, Quoc-Dien Trinh, Toni K Choueiri, Guru Sonpavde. Crit Rev Oncol Hematol 2015
72
16

Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
Jiali Liu, Ling Li, Ke Deng, Chang Xu, Jason W Busse, Per Olav Vandvik, Sheyu Li, Gordon H Guyatt, Xin Sun. BMJ 2017
34
16



Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.
Wei-Xiang Qi, Da-Liu Min, Zan Shen, Yuan-Jue Sun, Feng Lin, Li-Na Tang, Ai-Na He, Yang Yao. Int J Cancer 2013
66
16

Demystifying trial networks and network meta-analysis.
Edward J Mills, Kristian Thorlund, John P A Ioannidis. BMJ 2013
441
16

Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.
Husam Abdel-Qadir, Josee-Lyne Ethier, Douglas S Lee, Paaladinesh Thavendiranathan, Eitan Amir. Cancer Treat Rev 2017
113
16


Checking consistency in mixed treatment comparison meta-analysis.
S Dias, N J Welton, D M Caldwell, A E Ades. Stat Med 2010
16



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.